Analysis of the Genetic Landscape in the Evolution of Oligometastatic Prostate Cancer Through Peripheral Bioanalytes
Abstract
Approximately 1 in 9 men will develop prostate cancer during their lifetime. Although cure rates for early-stage(localized) disease can be high, the proportion of men presenting with metastatic disease has substantially increased. The standard of care for metastatic prostate cancer continues to be treatment with life prolonging, yet non-curative, systemic therapy. However, emerging data suggest an intermediate state of "oligometastatic" disease that represents a transition from localized to widely disseminated "polymetastatic" disease. We are currently conducting a trial (EXTEND, NCT03599765) in men with castration- sensitive (n=87) and -resistant (n=87, with lead-in phase [n=8] total n=182) metastatic prostate cancer to explore the hypothesis that oligometastatic disease represents a state of limited metastatic potential amenable to local consolidative therapy with curative intent. Current definitions of oligometastatic disease rely on conventional imaging, which can provide information about the number and location of lesions but not tumor biology. In this proposal, we aim to fill this gap in knowledge by leveraging banked tissue and longitudinally collected plasma samples from EXTEND by using recent advances in genomic and epigenomic techniques to develop sensitive assays to query changes in the prostate cancer genome, gene expression patterns, and DNA methylation profile to develop a multi-faceted understanding of the disease biology over time.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2023
- Accession Number
- AD1223120
Entities
People
- Alexander Sanchez Espitia
- Chad Tang
- Krishna Bhat
- Rakesh Trivedi
- Yi Zhong
Organizations
- The University of Texas MD Anderson Cancer Center